The rapid advancement of AI has positioned it as a transformative force in today's technological landscape. With the global AI market valued at USD 136.55 billion in 2022 and projected to grow at a CAGR of 37.3% from now to 2030, the influence of AI is poised to expand exponentially across various industries.

The rapid growth is driven by continuous research and innovation led by tech giants, shaping the adoption of advanced technologies in sectors such as automotive, healthcare, retail, finance, manufacturing, and more.

While tech behemoths frequently dominate the AI landscape, there is growing interest in smaller companies that offer unique perspectives and innovative solutions. These smaller players can bring fresh approaches to the table, carving out their niche in the AI market and capturing the attention of investors seeking untapped potential.

In this article, we will explore the diverse applications of AI across industries, focusing on promising smaller companies.

EPAZZ, INC. (OTC: EPAZ)

EPAZ is an emerging player in the drone industry through its spinoff company, ZenaDrone. ZenaDrone's flagship product, the ZenaDrone 1000, harnesses the power of AI and machine learning software to cater to sectors including the military, government, agriculture, and farming. With its intelligent capabilities, the ZenaDrone 1000 offers advanced solutions for industrial surveillance, inspection, and monitoring needs.

With a strong focus on innovation and protecting intellectual property, the company recently announced its ongoing efforts to file a series of AI-related patents for its drone technology. This strategic move underscores Epazz's commitment to maintaining a competitive edge and establishing itself as an emerging force in the drone market segment.

Epazz has already achieved a significant milestone by securing two patents for its cutting-edge drone technology, and it currently has two additional patents under review by the US Patent Office. Through an active pursuit of patents, Epazz aims to safeguard its valuable intellectual property while laying a solid foundation for future growth.

One area where EPAZ is pushing boundaries is by extending the flight time of the ZenaDrone 1000, its flagship product. Through innovative engineering and the implementation of a custom battery management system, the company has successfully increased flight durations.

What truly sets the ZenaDrone 1000 apart is its integration of AI, which enables continuous real-time monitoring and analysis of flight characteristics. By harnessing the power of AI, Epazz optimizes flight performance, resulting in improved efficiency and enhanced capabilities.

Epazz, Inc. (OTC: EPAZ) is strategically advancing its AI technology to expand its global presence across industries. The company's AI-driven drone solutions cater to the evolving needs of sectors like agriculture, industrial surveillance, and inspections.

Notably, EPAZ has attracted attention from prominent entities in recent months. The U.S. Air Force, U.S. Army, NATO partner countries, law enforcement departments, a prominent German rail line, and the Department of Public Expenditure and Reform of Ireland have all recognized the potential of Epazz's subsidiary, ZenaDrone, and its flagship product, the ZenaDrone 1000.

Investors should closely monitor Epazz's progress as it continues to innovate and leverage AI. With a growing portfolio of AI-related patents and a strong focus on enhancing the capabilities of the ZenaDrone 1000, Epazz is poised for substantial growth and market success in the thriving drone industry.

LANTERN PHARMA INC. (NASDAQ: LTRN)

LTRN is an emerging company in the fight against cancer, harnessing the power of AI technologies to drive innovative advancements in the field. The company's focus on machine learning, AI, and advanced genomics positions it at the forefront of cutting-edge cancer treatments.

At the core of Lantern Pharma's capabilities is its proprietary AI platform, RADR, which scans an astounding 25 billion data points to identify potential compounds that could benefit cancer patients. By leveraging the power of AI, Lantern Pharma is able to uncover valuable insights and patterns that may have otherwise been overlooked in the quest for effective cancer therapies.

One key aspect that sets Lantern Pharma apart is its ability to breathe new life into failed drugs from the past. Through its AI platform, the company effectively detects overlooked genomic signatures, unlocking the potential of existing compounds and paving the way for potential breakthroughs in cancer treatment. By repurposing and reevaluating these compounds, Lantern Pharma is able to explore novel therapeutic avenues and potentially offer hope to patients with limited treatment options.

Lantern Pharma's recent collaboration with Bielefeld University in Germany further highlights its commitment to innovation and scientific collaboration. The consortium's coordinator and well-known ADC expert Professor Norbert Sewald is leading a collaboration to create brand-new cryptophycin-antibody drug conjugates (ADCs).

By harnessing the power of AI, the company is poised to revolutionize cancer treatments, reduce timelines, and lower costs. As Lantern Pharma continues to make strides in the field.

REMARK HOLDINGS INC. (NASDAQ: MARK)

MARK is a provider of AI-powered analytics, computer vision, and smart agent solutions. The company offers an integrated suite of AI tools that enable organizations to gain insights into customer demographics and behavior, as well as detect and respond to potential security threats in real time.

With a team of experienced professionals, Remark has developed award-winning video analytics solutions that comply with GDPR and CCPA regulations. MARK's solutions cater to various sectors, including government agencies, hospitality, public safety, retail, and transportation.

MARK announced a significant company success on May 31, winning a significant contract worth over $6 million for a 30-month recurring revenue subscription. The contract involves equipping the police car fleet of the Rio de Janeiro police department with license plate and facial recognition capabilities.

This deployment, to be completed within 120 days, marks the first phase of a larger rollout for MARK. The technical due diligence period also presents additional revenue opportunities for subsequent phases. Remark AI has partnered with iProp.Tech, a local Brazilian system integrator, to ensure the successful execution and implementation of the project.

The success of this contract strengthens Remark AI's credibility and positions them to bid for a $130 million opportunity with the Sao Paulo City Government. Brazil's market potential is immense, with numerous states yet to explore AI solutions. The private sector, including condominiums and residences, also presents a promising opportunity for Remark AI.

Remark AI's AI solutions provide real-time identification capabilities for individuals and license plates of interest, significantly improving safety and security for the Rio de Janeiro police. This project serves as a milestone for Remark AI's expansion in Brazil and opens doors to further opportunities in the region.

VERSES (OTC: VRSSF)

VRSSF is a cognitive computing company operating within the next-generation of AI solutions. Their GIA flagship product, which enables distributed intelligence across various domains, is powered by their advanced KOSM network operating system. VERSES recently made a significant impact with their groundbreaking research paper on "Designing Explainable Artificial Intelligence." The paper focuses on developing AI systems that are transparent and interpretable, addressing the growing demand for trustworthy AI solutions.

By collaborating with renowned research institutions such as the Wellcome Centre for Human Neuroimaging and the Berlin School of Mind & Brain, VERSES demonstrates its commitment to advancing the field of AI. These collaborations enable VERSES to incorporate cutting-edge insights into their products and services, ensuring they stay ahead in the rapidly evolving AI landscape.

VERSES' emphasis on AI explainability aligns with global trends and regulatory demands. The research paper proposes an architecture that allows AI systems to track and explain the factors influencing their decisions. This approach aims to build trust and understanding among end-users, revolutionizing the way we interact with AI technology.

As a testament to their expertise, VERSES' breakthrough research will be showcased at an upcoming Active Inference conference. By actively participating in conferences and events, VERSES continues to contribute to the development of AI practices and solutions.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

CONTACT: CapitalGainsReport

Mark McKelvie

Editor

Markrmckelvie@gmail.com

585-301-7700

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE